{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:07:03Z","timestamp":1778746023014,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The standard treatment for colorectal cancer consists of surgery and chemotherapy, which can be combined to improve outcomes. Immune checkpoint inhibitors (ICI) are a significant advancement in the standard treatment of metastatic, unresectable colorectal cancer with deficient mismatch repair (dMMR). However, limited data are available about the use of ICI in the neoadjuvant and conversion settings. Here, we present two cases treated with ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Case 1: A 75-year-old male with a large, borderline resectable rectal cancer diagnosed as cT4bN1bM0 who underwent neoadjuvant chemotherapy, followed by combination ICI consisting of ipilimumab and nivolumab. After four courses of ICI, the tumor significantly shrank, but positron emission tomography still showed a positive result and R0 resection was performed. Pathological analysis revealed no residual cancer cells. The patient has been monitored without adjuvant chemotherapy, and no recurrences have occurred after one year. Case 2: A 60-year-old male with locally advanced sigmoid colon cancer who received neoadjuvant treatment with pembrolizumab. The tumor partially shrank after three courses, and continued pembrolizumab monotherapy resulted in further tumor shrinkage which still showed positive positron emission tomography. Curative sigmoidectomy with partial resection of the ileum and bladder was performed, and the pathological outcome was pCR. There was no viable tumor in the specimen. The patient has been monitored without adjuvant chemotherapy for six months, and no recurrence has been observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study reports two cases, including a large, borderline resectable rectal cancer after failure of chemotherapy followed by combination treatment with nivolumab and ipilimumab and one case of sigmoid colon cancer after pembrolizumab treatment, which resulted in pathological complete response. However, it remains unknown whether ICI therapy can replace surgery or diminish the optimal extent of resection, or whether adjuvant chemotherapy is needed after surgery in the case of achieving pCR after ICI therapy. Overall, this case report suggests that ICI before colorectal surgery can be effective and potentially a \u2018watch-and-wait\u201d strategy could be used for cases in which ICI is effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40792-024-01894-x","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:41:33Z","timestamp":1714560093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unanticipated pathological clearance in two cases of clinical T4b dMMR\/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results"],"prefix":"10.1186","volume":"10","author":[{"given":"Daigaku","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Ushigome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruriko","family":"Nishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Furukawa-Hibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"issue":"15","key":"1894_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329(15):1271\u201382. https:\/\/doi.org\/10.1001\/jama.2023.4428.","journal-title":"JAMA"},{"issue":"11","key":"1894_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","volume":"27","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27(11):1899\u2013903. https:\/\/doi.org\/10.1038\/s41591-021-01553-w.","journal-title":"Nat Med"},{"issue":"4","key":"1894_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.clcc.2017.03.005","volume":"16","author":"D Shahab","year":"2017","unstructured":"Shahab D, Gabriel E, Attwood K, et al. Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer. 2017;16(4):300\u20137. https:\/\/doi.org\/10.1016\/j.clcc.2017.03.005.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1894_CR4","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1016\/j.clcc.2020.06.004","volume":"19","author":"AAL Pereira","year":"2020","unstructured":"Pereira AAL, Fernandes GDS, Braga GTP, et al. Differences in pathology and mutation status among colorectal cancer patients younger than, older than, and of screening age. Clin Colorectal Cancer. 2020;19(4):e264\u201371. https:\/\/doi.org\/10.1016\/j.clcc.2020.06.004.","journal-title":"Clin Colorectal Cancer"},{"issue":"24","key":"1894_CR5","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.21.02541","volume":"40","author":"KK Ciombor","year":"2022","unstructured":"Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape. J Clin Oncol. 2022;40(24):2706\u201315. https:\/\/doi.org\/10.1200\/JCO.21.02541.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1894_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clcc.2022.01.009","volume":"21","author":"C Sun","year":"2022","unstructured":"Sun C, Espana S, Buges C, Layos L, Hierro C, Manzano JL. Treatment of advanced BRAF-mutated colorectal cancer: where we are and where we are going. Clin Colorectal Cancer. 2022;21(2):71\u20139. https:\/\/doi.org\/10.1016\/j.clcc.2022.01.009.","journal-title":"Clin Colorectal Cancer"},{"issue":"25","key":"1894_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med"},{"issue":"7","key":"1894_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.6004\/jnccn.2020.7558","volume":"18","author":"R Demisse","year":"2020","unstructured":"Demisse R, Damle N, Kim E, et al. Neoadjuvant immunotherapy-based systemic treatment in MMR-deficient or MSI-high rectal cancer: case series. J Natl Compr Cancer Netw. 2020;18(7):798\u2013804. https:\/\/doi.org\/10.6004\/jnccn.2020.7558.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"1894_CR9","doi-asserted-by":"publisher","first-page":"e2110","DOI":"10.1002\/onco.13955","volume":"26","author":"J Trojan","year":"2021","unstructured":"Trojan J, Stintzing S, Haase O, et al. Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H\/dMMR rectal cancer. Oncologist. 2021;26(12):e2110\u20134. https:\/\/doi.org\/10.1002\/onco.13955.","journal-title":"Oncologist"},{"issue":"2","key":"1894_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3816\/CCC.2001.n.010","volume":"1","author":"H Elsaleh","year":"2001","unstructured":"Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001;1(2):104\u20139. https:\/\/doi.org\/10.3816\/CCC.2001.n.010.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"1894_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1053\/j.gastro.2003.12.023","volume":"126","author":"JM Carethers","year":"2004","unstructured":"Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126(2):394\u2013401. https:\/\/doi.org\/10.1053\/j.gastro.2003.12.023.","journal-title":"Gastroenterology"},{"issue":"10","key":"1894_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3816\/CCC.2007.n.042","volume":"6","author":"E Odin","year":"2007","unstructured":"Odin E, Wettergren Y, Nilsson S, Carlsson G, Gustavsson B. Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels. Clin Colorectal Cancer. 2007;6(10):720\u20137. https:\/\/doi.org\/10.3816\/CCC.2007.n.042.","journal-title":"Clin Colorectal Cancer"},{"issue":"20","key":"1894_CR13","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219\u201326. https:\/\/doi.org\/10.1200\/JCO.2009.27.1825.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1894_CR14","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/j.clcc.2017.12.006","volume":"17","author":"S Armstrong","year":"2018","unstructured":"Armstrong S, Al-Ghawi H, Helft P, et al. Two months of therapy: a case of pathologic complete response to chemoimmunotherapy in a patient with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(2):e229\u201332. https:\/\/doi.org\/10.1016\/j.clcc.2017.12.006.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"1894_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clcc.2020.02.002","volume":"19","author":"J Thomas","year":"2020","unstructured":"Thomas J, Leal A, Overman MJ. Clinical development of immunotherapy for deficient mismatch repair colorectal cancer. Clin Colorectal Cancer. 2020;19(2):73\u201381. https:\/\/doi.org\/10.1016\/j.clcc.2020.02.002.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"1894_CR16","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/j.clcc.2020.09.004","volume":"20","author":"E McGillivray","year":"2021","unstructured":"McGillivray E, Farma J, Savage M, Hall MJ, Luo B, Jain R. Pathologic complete response in patient with ATM mutation after neoadjuvant FOLFOXIRI plus panitumumab therapy for locally advanced colon cancer: a case report. Clin Colorectal Cancer. 2021;20(2):e96\u20139. https:\/\/doi.org\/10.1016\/j.clcc.2020.09.004.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1894_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clcc.2021.05.008","volume":"20","author":"FT Tostes","year":"2021","unstructured":"Tostes FT, Fernandes I, Segatelli V, Callegaro D, Carmagnani PR. Response to pembrolizumab in advanced anal squamous cell carcinoma with high TMB and PD-L1 and PD-L2 amplification. Clin Colorectal Cancer. 2021;20(4):350\u20133. https:\/\/doi.org\/10.1016\/j.clcc.2021.05.008.","journal-title":"Clin Colorectal Cancer"},{"key":"1894_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejca.2022.07.016","volume":"174","author":"QX Wang","year":"2022","unstructured":"Wang QX, Xiao BY, Cheng Y, et al. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR\/MSI-H rectal cancer: a multicentre cohort study. Eur J Cancer. 2022;174:176\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.016.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1894_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clcc.2022.11.004","volume":"22","author":"F Pei","year":"2023","unstructured":"Pei F, Wu J, Zhao Y, et al. Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer. Clin Colorectal Cancer. 2023;22(1):85\u201391. https:\/\/doi.org\/10.1016\/j.clcc.2022.11.004.","journal-title":"Clin Colorectal Cancer"},{"key":"1894_CR20","unstructured":"NCCN. <(4) NCCN Guidelines_Colon Cancer. Version 2. 2023.pdf>. 2023;"},{"key":"1894_CR21","unstructured":"NCCN. <2023_NCCN-rectal_blocks.pdf>. 2023;"},{"issue":"10","key":"1894_CR22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argiles","year":"2020","unstructured":"Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291\u2013305. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.022.","journal-title":"Ann Oncol"},{"issue":"1","key":"1894_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1\u201342. https:\/\/doi.org\/10.1007\/s10147-019-01485-z.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"1894_CR24","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1159\/000519470","volume":"14","author":"T Yoshida","year":"2021","unstructured":"Yoshida T, Miki H, Satake H, et al. Pathological complete response of clinical T4b ascending colon cancer after preoperative chemotherapy using pembrolizumab. Case Rep Oncol Sep-Dec. 2021;14(3):1497\u2013504. https:\/\/doi.org\/10.1159\/000519470.","journal-title":"Case Rep Oncol Sep-Dec"},{"issue":"1","key":"1894_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12957-022-02624-z","volume":"20","author":"R Mori","year":"2022","unstructured":"Mori R, Uemura M, Sekido Y, et al. Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. World J Surg Oncol. 2022;20(1):166. https:\/\/doi.org\/10.1186\/s12957-022-02624-z.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"1894_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s40792-022-01580-w","volume":"8","author":"H Sawayama","year":"2022","unstructured":"Sawayama H, Miyamoto Y, Ogawa K, et al. Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review. Surg Case Rep. 2022;8(1):223. https:\/\/doi.org\/10.1186\/s40792-022-01580-w.","journal-title":"Surg Case Rep"},{"issue":"7","key":"1894_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2967\/jnumed.107.040436","volume":"48","author":"L Edouard","year":"2007","unstructured":"Edouard L, Geoffrey A, Arnaud C, et al. Noninvasive assessment of Crohn\u2019s disease intestinal lesions with (18)F-FDG PET\/CT. J Nucl Med. 2007;48(7):1053\u20139. https:\/\/doi.org\/10.2967\/jnumed.107.040436.","journal-title":"J Nucl Med"},{"issue":"4","key":"1894_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00259-013-2625-2","volume":"41","author":"S Babak","year":"2014","unstructured":"Babak S, Ali S, Alex B, et al. FDG PET\/CT in Crohn\u2019s disease: correlation of quantitative FDG PET\/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging. 2014;41(4):605\u201314. https:\/\/doi.org\/10.1007\/s00259-013-2625-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1894_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.biopha.2004.08.005","volume":"58","author":"C Capirci","year":"2004","unstructured":"Capirci C, Rubello D, Chierichetti F, et al. Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother. 2004;58(8):451\u20137. https:\/\/doi.org\/10.1016\/j.biopha.2004.08.005.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1894_CR30","doi-asserted-by":"publisher","first-page":"W202","DOI":"10.2214\/AJR.05.0902","volume":"187","author":"C Capirci","year":"2006","unstructured":"Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18-F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol. 2006;187(2):W202\u20138. https:\/\/doi.org\/10.2214\/AJR.05.0902.","journal-title":"Am J Roentgenol"},{"issue":"5","key":"1894_CR31","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.ijrobp.2008.10.064","volume":"74","author":"C Capirci","year":"2009","unstructured":"Capirci C, Rubello D, Pasini F, et al. The role of dual-time combined 18-fluorideoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiation Biol Phys. 2009;74(5):1461\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.064.","journal-title":"Int J Radiation Biol Phys."},{"issue":"3","key":"1894_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/annonc\/mdq433","volume":"22","author":"AA Martoni","year":"2011","unstructured":"Martoni AA, Di Fabio F, Pinto C, et al. Prospective study on the FDG-PET\/TC predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22(3):650\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdq433.","journal-title":"Ann Oncol"},{"issue":"4","key":"1894_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000345601","volume":"84","author":"B Chiara","year":"2013","unstructured":"Chiara B, Alessandra A, Simona F, et al. Is the standardized uptake value of FDG-PET\/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology. 2013;84(4):191\u20139. https:\/\/doi.org\/10.1159\/000345601.","journal-title":"Oncology"},{"issue":"1\u20132","key":"1894_CR34","first-page":"51","volume":"2","author":"JMC Won-Seok Jo","year":"2006","unstructured":"Won-Seok Jo JMC. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark. 2006;2(1\u20132):51\u201360.","journal-title":"Cancer Biomark"},{"issue":"6","key":"1894_CR35","first-page":"546","volume":"30","author":"ME Salem","year":"2016","unstructured":"Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30(6):546\u201362.","journal-title":"Oncology (Williston Park)"},{"issue":"11","key":"1894_CR36","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"55","author":"MD Jean-Fran\u00e7ois Bosset","year":"2006","unstructured":"Jean-Fran\u00e7ois Bosset MD, Laurence Collette PD, Gilles Calais MD, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;55(11):1114\u201323. https:\/\/doi.org\/10.1056\/NEJMoa060829.","journal-title":"N Engl J Med"},{"issue":"4","key":"1894_CR37","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/SLA.0000000000003051","volume":"271","author":"S Hasan","year":"2020","unstructured":"Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a national cancer database (NCDB) analysis. Ann Surg. 2020;271(4):716\u201323. https:\/\/doi.org\/10.1097\/SLA.0000000000003051.","journal-title":"Ann Surg"},{"issue":"4","key":"1894_CR38","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376. https:\/\/doi.org\/10.1038\/s41591-020-0805-8.","journal-title":"Nat Med"},{"issue":"7","key":"1894_CR39","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/bjs.8732","volume":"99","author":"R Glynne-Jones","year":"2012","unstructured":"Glynne-Jones R, Hughes R. Critical appraisal of the \u2018wait and see\u2019 approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99(7):897\u2013909. https:\/\/doi.org\/10.1002\/bjs.8732.","journal-title":"Br J Surg"},{"key":"1894_CR40","doi-asserted-by":"publisher","first-page":"42354","DOI":"10.18632\/oncotarget.6093","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, Liu H, Yin J, et al. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy-a cohort study. Oncotarget. 2015;6:42354.","journal-title":"Oncotarget"},{"issue":"4","key":"1894_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/DCR.0000000000000558","volume":"59","author":"SC Nahas","year":"2016","unstructured":"Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum. 2016;59(4):255\u201363. https:\/\/doi.org\/10.1097\/DCR.0000000000000558.","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"1894_CR42","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1245\/s10434-017-5841-3","volume":"24","author":"T Sammour","year":"2017","unstructured":"Sammour T, Price BA, Krause KJ, Chang GJ. Nonoperative management or \u2018watch and wait\u2019 for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol. 2017;24(7):1904\u201315. https:\/\/doi.org\/10.1245\/s10434-017-5841-3.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1894_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/DCR.0000000000000754","volume":"60","author":"JC Kong","year":"2017","unstructured":"Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following \u201cwatch and wait\u201d for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum. 2017;60(3):335\u201345. https:\/\/doi.org\/10.1097\/DCR.0000000000000754.","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"1894_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","volume":"2","author":"F Dossa","year":"2017","unstructured":"Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501\u201313. https:\/\/doi.org\/10.1016\/S2468-1253(17)30074-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10139","key":"1894_CR45","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","volume":"391","author":"MJM van der Valk","year":"2018","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(18)31078-X.","journal-title":"Lancet"},{"issue":"4","key":"1894_CR46","doi-asserted-by":"publisher","first-page":"e185896","DOI":"10.1001\/jamaoncol.2018.5896","volume":"5","author":"JJ Smith","year":"2019","unstructured":"Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5(4):e185896. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5896.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1894_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(20)30557-X","volume":"22","author":"LM Fernandez","year":"2021","unstructured":"Fernandez LM, Sao Juliao GP, Figueiredo NL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22(1):43\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(20)30557-X.","journal-title":"Lancet Oncol"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01894-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-024-01894-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01894-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:51:00Z","timestamp":1714560660000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-024-01894-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1186\/s40792-024-01894-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3301544\/v1","asserted-by":"object"}]},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was granted by the Institutional Review Board (IRB) of our institution (Reference number 60-19-0150). All participants provided their written informed consent prior to participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all participants prior to participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}